The latest price target for Bioventus (NASDAQ:BVS) was reported by JP Morgan on December 17, 2024. The analyst firm set a price target for $13.00 expecting BVS to rise to within 12 months (a possible 21.84% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Bioventus (NASDAQ:BVS) was provided by JP Morgan, and Bioventus upgraded their neutral rating.

The last upgrade for Bioventus Inc happened on December 17, 2024 when JP Morgan raised their price target to $13. JP Morgan previously had an underweight for Bioventus Inc.

The last downgrade for Bioventus Inc happened on November 22, 2022 when Craig-Hallum changed their price target from N/A to N/A for Bioventus Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bioventus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bioventus was filed on December 17, 2024 so you should expect the next rating to be made available sometime around December 17, 2025.

While ratings are subjective and will change, the latest Bioventus (BVS) rating was a upgraded with a price target of $12.00 to $13.00. The current price Bioventus (BVS) is trading at is $10.67, which is out of the analyst’s predicted range.